A detailed history of Meeder Asset Management Inc transactions in Vericel Corp stock. As of the latest transaction made, Meeder Asset Management Inc holds 2,174 shares of VCEL stock, worth $123,244. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,174
Holding current value
$123,244
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$42.25 - $53.56 $91,851 - $116,439
2,174 New
2,174 $91,000
Q3 2022

Nov 14, 2022

SELL
$22.62 - $32.54 $67 - $97
-3 Reduced 10.34%
26 $1,000
Q2 2022

Aug 08, 2022

SELL
$22.88 - $39.45 $137 - $236
-6 Reduced 17.14%
29 $1,000
Q1 2022

May 10, 2022

BUY
$31.69 - $43.29 $1,109 - $1,515
35 New
35 $1,000
Q4 2021

Feb 11, 2022

SELL
$35.2 - $52.6 $2,499 - $3,734
-71 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$46.35 - $59.75 $1,714 - $2,210
37 Added 108.82%
71 $3,000
Q2 2021

Aug 09, 2021

BUY
$47.2 - $67.81 $1,604 - $2,305
34 New
34 $2,000
Q1 2020

May 15, 2020

SELL
$7.25 - $19.22 $94,213 - $249,763
-12,995 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$13.77 - $19.2 $80,265 - $111,916
5,829 Added 81.34%
12,995 $227,000
Q3 2019

Oct 17, 2019

BUY
$14.93 - $19.83 $106,943 - $142,042
7,163 Added 238766.67%
7,166 $108,000
Q2 2019

Aug 05, 2019

SELL
$15.01 - $18.89 $108,357 - $136,366
-7,219 Reduced 99.96%
3 $0
Q1 2019

Apr 16, 2019

BUY
$16.23 - $20.29 $23,647 - $29,562
1,457 Added 25.27%
7,222 $128,000
Q4 2018

Jan 17, 2019

BUY
$10.77 - $18.44 $13,828 - $23,676
1,284 Added 28.65%
5,765 $100,000
Q3 2018

Nov 02, 2018

BUY
$9.1 - $14.8 $40,777 - $66,318
4,481 New
4,481 $0

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.67B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.